BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC for BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 6, 2022 | $90,000 | Replaced |
| 4th Quarter - Termination | Jan 6, 2022 | $90,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Health Issues HCR
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Medicare/Medicaid MMM
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Insurance INS
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Pharmacy PHA
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.